阿布昔替尼治疗中重度特应性皮炎长达2年的长期疗效
JADE EXTEND长期扩展研究纳入既往阿布昔替尼试验的中重度特应性皮炎患者,评估至112周的疗效与患者报告结局。数据显示,200 mg和100 mg组在多个严格终点上均维持较高应答比例,包括IGA 0/1、EASI-75/90/100及瘙痒改善,且生活质量指标持续改善。
要点
- 阿布昔替尼200 mg和100 mg治疗至112周,IGA 0/1应答率分别为57%和52%。
- EASI-75应答率分别为84%和78%,EASI-90为61%和54%,EASI-100为26%和21%。
- 瘙痒改善(PP-NRS4)分别为70%和58%,DLQI 0/1为43%和41%。
核心结论
- 阿布昔替尼治疗中重度特应性皮炎至2年,在相当比例患者中产生有临床意义的疗效和患者报告结局改善,包括高阈值终点。
研究设计与样本
- JADE EXTEND(NCT03422822)是一项正在进行的3期长期扩展研究,纳入来自MOA、MONO-1、MONO-2、COMPARE、TEEN和DARE等合格试验的中重度特应性皮炎患者。
主要发现
- 截至数据截止日(2022年9月5日),403例(42%)和425例(56%)患者分别接受阿布昔替尼200 mg和100 mg治疗≥112周。
- 第112周时,200 mg和100 mg组的IGA 0/1应答率分别为57%和52%,EASI≤7为81%和77%。
- 第112周时,200 mg和100 mg组的EASI-75应答率分别为84%和78%,EASI-90为61%和54%,EASI-100为26%和21%。
- 第112周时,200 mg和100 mg组的PP-NRS4应答率分别为70%和58%,PP-NRS 0/1为43%和33%,EASI-90+PP-NRS 0/1为37%和30%。
- 第112周时,200 mg和100 mg组的DLQI 0/1分别为43%和41%,CDLQI 0/1为59%和39%,PtGA 0/1为75%和72%,POEM≥4为88%和81%。
关键数值与推荐
- 疗效评估包括IGA 0/1、EASI≤7、EASI-75/-90/-100、PP-NRS4、PP-NRS 0/1及EASI-90+PP-NRS 0/1。
- 患者报告结局包括DLQI 0/1、CDLQI 0/1、PtGA 0/1和POEM≥4。
临床怎么用
- 对于中重度特应性皮炎需长期系统治疗的患者,阿布昔替尼100 mg或200 mg每日一次可在2年内维持多维度疗效,包括瘙痒和生活质量改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abrocitinib treatment previously showed clinically meaningful improvements in skin signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) up to 48 weeks, with a manageable safety profile. OBJECTIVE: To further evaluate long-term efficacy and patient-reported outcomes (PROs) with abrocitinib in patients with moderate-to-severe AD up to 112 weeks of treatment. METHODS: JADE EXTEND (NCT03422822), an ongoing, phase 3, long-term extension study of previous abrocitinib trials, includes patients from qualifying trials MOA (NCT03915496), MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), TEEN (NCT03796676) and DARE (NCT04345367). Efficacy assessments include the proportion of patients achieving IGA score of 0 or 1 (IGA 0/1); absolute Eczema Area and Severity Index ≤7 (EASI ≤ 7), ≥75%/≥90%/100% improvement in EASI (EASI-75/-90/-100); ≥4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4); PP-NRS score of 0 or 1 (PP-NRS 0/1); EASI-90 + PP-NRS 0/1. PROs include Dermatology Life Quality Index score of 0 or 1 (DLQI 0/1), Children's Dermatology Life Quality Index score of 0 or 1 (CDLQI 0/1), Patient Global Assessment score of 0 or 1 (PtGA 0/1), and ≥4-point improvement in Patient-Oriented Eczema Measure (POEM ≥ 4). Data cut-off: 5 September 2022. RESULTS: At data cut-off, 403 (42%) and 425 (56%) patients received abrocitinib 200 mg and abrocitinib 100 mg, respectively, for ≥112 weeks. Week 112 efficacy responses were IGA 0/1 57% and 52%; EASI ≤7 81% and 77%; EASI-75 84% and 78%; EASI-90 61% and 54%; EASI-100 26% and 21%; PP-NRS4 70% and 58%; PP-NRS 0/1 43% and 33%; EASI-90 + PP-NRS 0/1 37% and 30%. Week 112 PROs were DLQI 0/1 43% and 41%; CDLQI 0/1 59% and 39%; PtGA 0/1 75% and 72%; POEM ≥4 88% and 81%. CONCLUSIONS: Abrocitinib treatment resulted in clinically meaningful outcomes and improvements in PROs, including high-threshold endpoints, in substantial proportions of patients with moderate-to-severe AD up to 2 years. Atopic dermatitis (AD) is a chronic inflammatory skin disease that needs long‐term disease control as an important treatment goal. Patients with AD whose disease is not adequately controlled with topical therapy require treatment with systemic agents that are effective and well tolerated. Abrocitinib is an approved treatment for people with moderate or severe AD that is taken as a once‐daily pill in either of two doses: 100 or 200 mg. The aim of this study was to analyse the efficacy of long‐term use of abrocitinib over 2 years of treatment. Participants in the long‐term extension study, JADE EXTEND, were originally in other, shorter abrocitinib studies and given the opportunity to extend their treatment. Participants were adults or adolescents (12 years and older) with moderate‐to‐severe AD that was not adequately controlled by topical treatments. The study involved over 1700 people from multiple countries around the world. People received either abrocitinib 100 or 200 mg once a day. The effect of treatment was measured by looking at the amount of skin affected, the severity of AD symptoms, the level of itch and the impact AD has on people's quality of life. In the first 12 weeks, both doses of abrocitinib rapidly improved the signs and symptoms of AD. Most people achieved a mild AD state within 12 weeks, and this was also observed during long‐term treatment. In conclusion, long‐term treatment with abrocitinib improves AD symptoms out to 2 years.
引用
- Gooderham MJ, Silverberg JI, De Bruin-Weller M, et al. Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years. J Eur Acad Dermatol Venereol. 2026. PMID: 42047411. doi:10.1111/jdv.70439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。